Abstract Library

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#3327 Increased expression of cytochrome P450 3A4 in pancreatic neuroendocrine tumor cells promotes drug resistance

Introduction: Pancreatic neuroendocrine tumors (PNETs) are slow growing, but often metastasize to the liver. Several systemic treatment options are available for metastatic PNETs but unfortunately fail to improve survival. Hence a better understanding of PNET biology and new therapies are required. In an attempt to identify new drugs for metastatic PNETs, our group performed gene expression analysis of primary PNETs and PNETs that metastasized to lymph nodes and/or liver and identified genes and drug candidates that could potentially help treat metastatic PNETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Tran C

Authors: Tran C, Li G, Sherman S, Howe J, Ear P,

Keywords: PNET, metastases, drug resistance, liver microenvironment, etoposide, CYP3A4,

#1927 Conditional Survival (CS) Analysis of Liver Resection (LR) for Gastro-Entero-Pancreatic Neuroendocrine Tumor (GEP-NET).

Introduction: LR with curative intent in metastatic GEP-NET is rarely feasible associated with improved survival and symptoms control. CS is the probability that pts will survive an additional number of yrs given that they have already survived at a certain interval

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: coppa J

Authors: Coppa J, Bongini M, Scotti M, Flores M, Bianchi Z,

Keywords: Survival, Liver resection,GEP-NET,